Akebia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Akebia Therapeutics Inc AKBA.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of four analysts for the quarter was for a loss of 4 cents per share. Wall Street expected results to range from -8 cents to -2 cents per share.

• Revenue rose 75.8% to $57.34 million from a year ago; analysts expected $44.88 million.

• Akebia Therapeutics Inc's reported EPS for the quarter was 3 cents​.

• The company reported quarterly net income of $6.11 million.

• Akebia Therapeutics Inc shares had risen by 28.1% this quarter and gained 29.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 28.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Akebia Therapeutics Inc is $6.75

This summary was machine generated from LSEG data May 8 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)